Drs. Ross Levine, David Steensma, and a surprise recurring guest form a roundtable on today’s show to discuss making the career choice of a non-PhD lab-based scientist and what that entails on a day-to-day basis, how mentoring individuals in other labs is a rewarding and continuous process, what makes a good mentor, managing and securing grant funding for lab research (including the secrets of writing effective grants), making the transition from the clinic to industry and the day-to-day expectations in this environment, and misconceptions of the intentions and cultures of pharmaceutical companies. They wrap up the discussion with a commentary on the overabundance of medical meetings and how they are managing their conference travel schedules against their COVID wariness.
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
